<DOC>
	<DOCNO>NCT01628471</DOCNO>
	<brief_summary>Lung cancer one prevalent lethal neoplasias world . Currently use chemotherapy regimens disappointing improve overall survival . Decitabine S-phase pyrimidine analog induces DNA hypomethylation . This drug currently use treat Myelodysplastic Syndrome ( MDS ) study treatment leukemia . Genistein , soy extract non-toxic isoflavone phytoestrogen , show inhibit activity cell signal pathway , drive tyrosine kinase . Results vitro experiment unambiguously demonstrate combination two compound induces synergistic reduction multiplication lung , colon , breast leukemic cancer cell . Consequently , clinical evaluation drug combination warrant Non Small Cell Lung Cancer ( NSCLC ) , hypothezised new regimen safely improve overall tumor response rate cancer progression free survival . The propose trial two part study : The phase I part open-label , dose-escalation evaluation subject advance solid tumor fail standard therapy curative therapeutic option exists . A cohort three subject treat per dose level . One cycle 28 day . Five different , increase dose level range 60 mg/m2 500 mg/m2 IV decitabine combine fixed oral dose 150 mg BID genistein test . The Maximum Tolerated Dose ( MTD ) determine base occurrence Dose Limiting Toxicities ( DLTs ) . In phase IIa part study , Stage IIIb IV advance NSCLC patient treat recommended decitabine MTD dose combine genistein . Safety preliminary efficacy assess . It expect maximum sample 46 patient enrolled trial .</brief_summary>
	<brief_title>MTD Determination , Safety Efficacy Decitabine-Genistein Drug Combination Advanced Solid Tumors Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>Written Informed Consent . Males female . 1875 year . Histologically cytologically confirm nonestrogen dependent advance solid malignancy fail standard therapy and/or curative therapeutic option exists ( phase I ) ; Histologically cytologically confirm NSCLC stage IIIb IV ( phase IIa ) fail ineligible standard therapy . One tumor lesion measurable RECIST criterion Life expectancy least 3 month . ECOG performance 2 less . Prior decitabine genistein therapy . Received cytotoxic agent , hormonal therapy , radiation therapy , target cancer therapy investigational agent within 4 week prior study entry . Patients confirm estrogen receptorpositive cancer , patient primary breast endometrial cancer phenotyping analysis perform . Presence uncontrolled brain metastasis leptomeningeal disease . Uncontrolled cardiovascular disorder , include symptomatic heart failure , unstable angina cardiac arrhythmia . Inadequate baseline organ function show follow laboratory value : Hemoglobin &lt; 90 g/L Absolute neutrophil count &lt; 1,500 /microliter Platelet count &lt; 100,000 /microliter Total bilirubin &gt; 1.5 ULN AST ALT &gt; 2.5 ULN Creatinine clearance &lt; 60 ml/min To dependent oxygen treatment . Active infection require antibiotic . Pregnancy breastfeed . All woman childbearing potential must negative pregnancy test prior first receive protocol therapy . Known allergic reaction soy derivative deoxycytidine derivative . Active alcohol drug abuse . Any comorbid condition judgment investigator render subject high risk treatment complication reduce probability assess clinical effect . Other malignancy diagnose within last 5 year exception Basal Cell Carcinoma skin . Gastrointestinal disorder abnormality may interfere absorption genistein . Patients unable comply study protocol followup schedule psychological , familial , sociological geographical reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Phase I b : advanced solid malignancy</keyword>
	<keyword>Phase II : stage III b IV , Non Small Cell Lung Cancer</keyword>
</DOC>